PAEP (Progestagen Associated Endometrial Protein)

Our study suggests that PAEP may be a potential therapeutic target for ccRCC, providing a new theoretical basis for ccRCC clinical immunotherapy.

Further analysis confirmed that BCL11B and PAEP expression levels were significantly associated with immune cell infiltration and immune regulatory activity. MAGEA3/6 expression defines immune subtypes in GC and highlights potential targets for immunotherapy.

Two HDACi were tested using an endometrial xenograft tumor model: entinostat, an oral drug, and romidepsin, an IV drug. Many of the upregulated drug efficacy markers predict favorable patient outcomes, while downregulated genes predict worse survival. Here, our current data suggests that romidepsin is a more potent HDACi that has the potential to achieve more robust upregulation of PR expression and may be a more promising candidate for future clinical trials.